Standard Operating Procedures in Experimental Liver Research: Thioacetamide model in mice and rats

Laboratory Animals

Volumn 49, Issue , 2015, Pages 21-29

  Wallace, Mc ^a   Hamesch, K ^b   Lunova, M ^b   Kim, Y ^d   Weiskirchen, R ^b   Strnad, P ^c   Friedman, Scott L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d Kyung Hee University College of Medicine   (South Korea)

Author keywords

animal models; cirrhosis; CYP2E1; hepatotoxin; liver fibrosis

Indexed keywords

THIOACETAMIDE;

ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; EXPERIMENTAL LIVER CIRRHOSIS; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LABORATORY; MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RAT; STANDARDS; TIME FACTOR;

ADMINISTRATION, ORAL; ANIMALS; DISEASE MODELS, ANIMAL; GUIDELINES AS TOPIC; HUMANS; INJECTIONS, INTRAPERITONEAL; LABORATORY ANIMAL SCIENCE; LIVER CIRRHOSIS, EXPERIMENTAL; MICE; RATS; THIOACETAMIDE; TIME FACTORS;

EID: 84979859673     PISSN: 00236772     EISSN: 17581117     Source Type: Journal    
DOI: 10.1177/0023677215573040     Document Type: Article

References (42)

1. Childs JFL Siegler EA. Controlling orange decay. Ind Eng Chem 1946; 38: 82–87.
2. Fitzhugh OG Nelson AA. Liver tumors in rats fed thiourea or thioacetamide. Science 1948; 108: 626–628.
3. Dashti H Jeppsson B Hägerstrand I. Thioacetamide- and carbon tetrachloride-induced liver cirrhosis. Eur Surg Res 1989; 21: 83–91.
4. Müller A Machnik F Zimmermann T Schubert H. Thioacetamide-induced cirrhosis-like liver lesions in rats – usefulness and reliability of this animal model. Exp Pathol 1988; 34: 229–236.
5. Muñoz Torres E Paz Bouza JI López Bravo A Abad Hernández MM Carrascal Marino E. Experimental thioacetamide-induced cirrhosis of the liver. Histol Histopathol 1991; 6: 95–100.
6. Peeling J Shoemaker L Gauthier T Benarroch A Sutherland GR Minuk GY. Cerebral metabolic and histological effects of thioacetamide-induced liver failure. Am J Physiol 1993; 265: G572–G578.
7. Butterworth RF Norenberg MD Felipo V Ferenci P Albrecht J Blei AT. Members of the ISHEN Commission on Experimental Models of HE. Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int 2009; 29: 783–788.
8. Kreft B Dombrowski F Block W Bachmann R Pfeifer U Schild H. Evaluation of different models of experimentally induced liver cirrhosis for MRI research with correlation to histopathologic findings. Invest Radiol 1999; 34: 360–366.
9. Li X Benjamin IS Alexander B. Reproducible production of thioacetamide-induced macronodular cirrhosis in the rat with no mortality. J Hepatol 2002; 36: 488–493.
10. Laleman W Vander Elst I Zeegers M. A stable model of cirrhotic portal hypertension in the rat: thioacetamide revisited. Eur J Clin Invest 2006; 36: 242–249.
11. Kimura M Fujii Y Yamamoto R. Involvement of multiple cell cycle aberrations in early preneoplastic liver cell lesions by tumor promotion with thioacetamide in a two-stage rat hepatocarcinogenesis model. Exp Toxicol Pathol 2013; 65: 979–988.
12. Kornek M Raskopf E Guetgemann I. Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1. J Hepatol 2006; 45: 370–376.
13. Wang X Lopategi A Ge X. Osteopontin induces ductular reaction contributing to liver fibrosis. Gut 2014; 63: 1805–1818.
14. Traber PG Chou H Zomer E. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One 2013; 8: e75361–e75361.
15. Dyroff MC Neal RA. Studies of the mechanism of metabolism of thioacetamide S-oxide by rat liver microsomes. Mol Pharmacol 1983; 23: 219–227.
16. Hunter AL Holscher MA Neal RA. Thioacetamide-induced hepatic necrosis. I. Involvement of the mixed-function oxidase enzyme system. J Pharmacol Exp Ther 1977; 200: 439–448.
17. Zimmermann C Ferenci P Pifl C. Hepatic encephalopathy in thioacetamide-induced acute liver failure in rats: characterization of an improved model and study of amino acid-ergic neurotransmission. Hepatology 1989; 9: 594–601.
18. Strnad P Tao GZ Zhou Q. Keratin mutation predisposes to mouse liver fibrosis and unmasks differential effects of the carbon tetrachloride and thioacetamide models. Gastroenterology 2008; 134: 1169–1179.
19. Jang JH Kang KJ Kim YH Kang YN Lee IS. Reevaluation of experimental model of hepatic fibrosis induced by hepatotoxic drugs: an easy, applicable, and reproducible model. Transplant Proc 2008; 40: 2700–2703.
20. Hajovsky H Hu G Koen Y. Metabolism and toxicity of thioacetamide and thioacetamide S-oxide in rat hepatocytes. Chem Res Toxicol 2012; 25: 1955–1963.
21. Lewis RJ Sr Sax NI. Sax's dangerous properties of industrial materials 1996; Volumes 1–3. 9th ed. New York: Van Nostrand Reinhold.
22. Kang JS Wanibuchi H Morimura K. Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity. Toxicol Appl Pharmacol 2008; 228: 295–300.
23. Chilakapati J Korrapati MC Shankar K. Role of CYP2E1 and saturation kinetics in the bioactivation of thioacetamide: effects of diet restriction and phenobarbital. Toxicol Appl Pharmacol 2007; 219: 72–84.
24. Jeong DH Jang JJ Lee SJ. Expression patterns of cell cycle-related proteins in a rat cirrhotic model induced by CCl4 or thioacetamide. J Gastroenterol 2001; 36: 24–32.
25. Staňková P Kučera O Lotková H Roušar T Endlicher R Cervinková Z. The toxic effect of thioacetamide on rat liver in vitro. Toxicol In Vitro 2010; 24: 2097–2103.
26. Koen YM Sarma D Hajovsky H. Protein targets of thioacetamide metabolites in rat hepatocytes. Chem Res Toxicol 2013; 26: 564–574.
27. Al-Bader A Mathew TC Abul H Al-Sayer H Singal PK Dashti HM. Cholangiocarcinoma and liver cirrhosis in relation to changes due to thioacetamide. Mol Cell Biochem 2000; 208: 1–10.
28. Popov Y Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009; 50: 1294–1306.
29. Zimmermann T Müller A Machnik G Franke H Schubert H Dargel R. Biochemical and morphological studies on production and regression of experimental liver cirrhosis induced by thioacetamide in Uje:WIST rats. Z Versuchstierkd 1987; 30: 165–180.
30. Salguero Palacios R Roderfeld M. Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice. Lab Invest 2008; 88: 1192–1203.
31. Walkin L Herrick SE Summers A. The role of mouse strain differences in the susceptibility to fibrosis: a systematic review. Fibrogenesis Tissue Repair 2013; 6: 18–18.
32. Yang MC Chang CP Lei HY. Induction of liver fibrosis in a murine hepatoma model by thioacetamide is associated with enhanced tumor growth and suppressed antitumor immunity. Lab Invest 2010; 90: 1782–1793.
33. Schnur J Olah J Szepesi A Nagy P Thorgeirsson S. Thioacetamide-induced hepatic fibrosis in transforming growth factor β-1 transgenic mice. Eur J Gastroenterol Hepatol 2004; 16: 127–133.
34. Sarma D Hajovsky H Koen YM. Covalent modification of lipids and proteins in rat hepatocytes and in vitro by thioacetamide metabolites. Chem Res Toxicol 2012; 25: 1868–1877.
35. Honda H Ikejima K Hirose M. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 2002; 36: 12–21.
36. Wasmuth HE Lammert F Zaldivar MM. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 2009; 137: 309–319.
37. Tuñón MJ Alvarez M Culebras JM González-Gallego J. An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure. World J Gastroenterol 2009; 15: 3086–3098.
38. Avraham Y Grigoriadis N Poutahidis T. Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. Br J Pharmacol 2011; 162: 1650–1658.
39. Becker FF. Thioacetamide hepatocarcinogenesis. J Natl Cancer Inst 1983; 71: 553–558.
40. Munoz Torres E Paz Bouza JI Lopez Bravo A Abad Hernandez MM Carrascal Marino E. Experimental thioacetamide-induced cirrhosis of the liver. Histol Histopathol 1991; 6: 95–100.
41. Mueller K Sunami Y Stuetzle M. CHOP-mediated hepcidin suppression modulates hepatic iron load. J Pathol 2013; 231: 532–542.
42. Zaldivar MM Pauels K von Hundelshausen P. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 2010; 51: 1345–1353.